Front Cover: [18F]NP3-627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System (ChemMedChem 4/2025)

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL ChemMedChem Pub Date : 2025-02-17 DOI:10.1002/cmdc.202580401

Dr. David M. Whitehead, Dr. Christian Fischer, Dr. Emmanuelle Briard, Dr. Christopher J. Farady, Nadège Graveleau, Joel Karrer, Dr. Klemens Kaupmann, Dr. Guillaume Lapointe, Dr. Angela Mackay, Lisa Reichert, Michael Wright, Dr. Linjing Mu, Dr. Yves P. Auberson

{"title":"Front Cover: [18F]NP3-627, a Candidate PET Imaging Agent Targeting the NLRP3 Inflammasome in the Central Nervous System (ChemMedChem 4/2025)","authors":"Dr. David M. Whitehead, Dr. Christian Fischer, Dr. Emmanuelle Briard, Dr. Christopher J. Farady, Nadège Graveleau, Joel Karrer, Dr. Klemens Kaupmann, Dr. Guillaume Lapointe, Dr. Angela Mackay, Lisa Reichert, Michael Wright, Dr. Linjing Mu, Dr. Yves P. Auberson","doi":"10.1002/cmdc.202580401","DOIUrl":null,"url":null,"abstract":"<p>The image shows the structure of the positron emission tomography (PET) imaging agent [<sup>18</sup>F]NP3-627, which can penetrate the brain and bind to the NACHT domain of NLRP3. In the background, we see the structure of the NLRP3 inflammasome complex, whose increased expression in inflammatory conditions offers the potential for [<sup>18</sup>F]NP3-627 to quantify inflammation in e.g., Alzheimer's disease, multiple sclerosis, or associated with other causes of neurodegeneration. Such a biomarker will facilitate the development of anti-inflammatory drugs acting on the NLRP3 inflammasome, as novel treatments for these conditions. More details can be found in article 10.1002/cmdc.202400816 by Yves P. Auberson and co-workers.<figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure>\n </p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 4","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.202580401","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cmdc.202580401","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The image shows the structure of the positron emission tomography (PET) imaging agent [¹⁸F]NP3-627, which can penetrate the brain and bind to the NACHT domain of NLRP3. In the background, we see the structure of the NLRP3 inflammasome complex, whose increased expression in inflammatory conditions offers the potential for [¹⁸F]NP3-627 to quantify inflammation in e.g., Alzheimer's disease, multiple sclerosis, or associated with other causes of neurodegeneration. Such a biomarker will facilitate the development of anti-inflammatory drugs acting on the NLRP3 inflammasome, as novel treatments for these conditions. More details can be found in article 10.1002/cmdc.202400816 by Yves P. Auberson and co-workers.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

图片显示的是正电子发射断层扫描（PET）成像剂[18F]NP3-627 的结构，它可以穿透大脑并与 NLRP3 的 NACHT 结构域结合。在背景中，我们看到了 NLRP3 炎性体复合物的结构，其在炎症条件下的表达量增加为 [18F]NP3-627 提供了量化阿尔茨海默病、多发性硬化症等炎症或与其他原因相关的神经变性的潜力。这种生物标志物将有助于开发作用于 NLRP3 炎性体的抗炎药物，作为治疗这些疾病的新型疗法。更多详情请见伊夫-P-奥伯森及其合作者撰写的文章 10.1002/cmdc.202400816。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.